Sequential Treatment of Cabozantinib for Advanced Renal Cell Carcinoma (RCC)

This study tests whether restarting cabozantinib — a targeted therapy drug — after a treatment break can be beneficial for people with advanced kidney cancer (renal cell carcinoma) whose disease responded for at least 6 months on their first course of cabozantinib. **You may be eligible if...** - You have advanced kidney cancer that progressed after a prior course of cabozantinib, but only after at least 6 months of benefit - You were able to tolerate cabozantinib at 60mg daily previously - You have measurable disease on imaging - You are 18 or older with adequate organ function - Prior immunotherapy (PD-1/PD-L1 inhibitors) is allowed **You may NOT be eligible if...** - Your kidney cancer did not benefit from cabozantinib for at least 6 months - You have untreated brain metastases causing symptoms - You are on certain blood thinners (warfarin, dabigatran, clopidogrel) - You have had a heart attack, stroke, or serious blood clot in the past 6 months - You have a serious active gastrointestinal condition (ulcers, perforation risk, bleeding) - You are pregnant or breastfeeding - You cannot swallow tablets Talk to your doctor to see if this trial is right for you.